The life science industry contributes to Swedish exports and provides many jobs for highly skilled people. At the same time, the industry has gone through some difficult years, such as AstraZeneca’s high-profile closures.
On behalf of Vinnova, the Swedish Agency for Growth Analysis has written the report Growth in the Swedish Life Science industry in 2012-14 – continued decline or new beginning? The report’s author Carl Wadell, Theme Manager Research Policy and Life Sciences, Growth Analysis, presents the survey at the breakfast seminar organized by IVA’s Department of Biotechnology.
It will be discussed by, among others, Jenni Nordborg, Director and Head of Department Health, Vinnova,Björn Odlander, Founding Partner, HealthCap and Anna Sandström, Director Science Relations, AstraZeneca.
Moderator: Martin Wikström, IVA
Welcome!
